
-
Tarsus Pharmaceuticals NASDAQ:TARS Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.
Location: | Website: www.tarsusrx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.585B
Cash
317M
Avg Qtr Burn
-25.05M
Short % of Float
25.20%
Insider Ownership
8.78%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XDEMVY (TP-03) Details Eye disease , Demodex Blepharitis | Approved Quarterly sales | |
TP-03 Details Meibomian Gland Disease , Demodex Blepharitis | Phase 3 Update | |
TP-03 Details Meibomian Gland Disease | Phase 2a Update | |
TP-05 Details Lyme disease | Phase 2a Update | |
TP-04 Details Papulopustular rosacea | Phase 2a Update |